NCAB Discusses the Proposal
Since changes in funding of the cancer centers will likely produce profound changes, NCAB discussion of the proposal warrants attention. A partial transcript of discussion appears below.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
